Management of Erdafitinib, a pan-FGFR kinase inhibitor, treatment-emergent adverse events
Erdafitinib was US FDA approved for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3/2 alterations who progressed on ≥ 1 line of prior platinum-based chemotherapy. In this MEDtalk Arlene O. Siefker-Radtke presents how the treatment-emergent adverse events mostly were managed with concomitant treatment and dose modifications, so the patients could stay in treatment with the fibroblast growth factor receptor, Erdafitinib inhibitor.
